Clinical Takeaway
In a controlled crossover trial of 25 healthy males, CBD at both low and high single doses showed no direct effect on cortical excitability compared to placebo, suggesting CBD alone may not carry intrinsic anti-epileptic properties in healthy brain tissue. This supports the hypothesis that CBD’s seizure-reducing benefits in conditions like Dravet syndrome and Lennox-Gastaut syndrome may depend largely on its pharmacokinetic interaction with clobazam rather than a standalone mechanism. Clinicians should interpret CBD monotherapy data cautiously when considering its role outside of established adjunctive treatment protocols.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s anti-seizure efficacy in approved indications may derive primarily from drug-drug interactions rather than direct effects on neuronal excitability, which has significant implications for predicting its efficacy in seizure disorders treated without concurrent clobazam. Understanding CBD’s mechanism of action is critical for clinicians prescribing it as monotherapy versus adjunctive therapy and for identifying patient populations most likely to benefit. These findings may explain variable treatment responses across different epilepsy syndromes and inform more rational polypharmacy strategies in clinical seizure management.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This rigorously designed crossover trial challenges a commonly held assumption that CBD exerts direct anti-seizure effects through cortical excitability modulation, instead suggesting its clinical benefit in Dravet and Lennox-Gastaut syndromes may be primarily mediated through pharmacokinetic interactions with concurrent medications like clobazam rather than through intrinsic neurophysiologic action. While the study’s controlled design and objective neurophysiologic measurements strengthen confidence in the negative finding, the results do not exclude other potential mechanisms of CBD’s therapeutic effect, such as anti-inflammatory pathways, effects on subcortical structures, or interactions with seizure propagation networks that electrocorticography may not fully capture. The absence of direct cortical effects also does not necessarily predict clinical efficacy, as demonstrated by the documented seizure reduction in FDA-approved indications, underscoring an important gap between bench-level neurophysiology and bedside clinical outcomes. For clinicians prescribing CBD, this evidence reinforces the importance